Cerebral Perfusion in a Patient with Dengue Hemorrhagic Fever
Author: Nitamar Abdala, MD, Radiology Professor, and Carolina Salazar, MD, Radiology Resident UMDI – Unidade Mogiana de Diagóstico por Imagem, São Paulo, Brazil
A 53 year old male patient with acute high intensity headache episodes and syncope (nausea) one month ago, left hemiplegics, and no more associated symptoms, was referred to the hospital. The patient had a history of hypertension with drug control and Dengue Hemorrhagic five years ago. Patients that suffer from Dengue Hemorrhagic can eventually have low blood flow with hypo cerebral perfusion which can cause cerebral infarction like “watershed”, which means, stroke in the frontier areas. Most of these lesions occur between the anterior and median cerebral arteries, as well as in the basal ganglia. Since this patient had an old stroke possibly caused by an ischemic event related to Dengue Hemorrhagic five years ago and moreover the patient still lives in the endemic area, it was suspected that the current symptoms could be related to the cerebral hypo perfusion.
Diagnosis and comments CT data acquired with the first SOMATOM Spirit in Brazil shows a lesion detected at right basal ganglia interpreted as encephalic scar from previous event. The current CT Perfusion study shows signals that can be related to hypo perfusion of left basal ganglia.
Dengue / Dengue Hemorrhagic Fever Dengue and dengue hemorrhagic fever (DHF) are acute febrile diseases, found in the tropics, with a geographical spread similar to malaria. Caused by Flavivirus, the disease is transmitted to humans by the mosquito Aedes aegypti. The disease is manifested by a sudden onset of fever, with severe headache, joint and muscular pains (myalgias and arthralgias, severe pain gives it the name break-bone fever), leukopenia and rashes. The dengue rash is characteristically bright red and covers most of the body. DHF also shows higher fever, hemorrhagic phenomena, thrombocytopenia, and hemoconcentration. In around 5 percent of cases there is dengue shock syndrome (DDS) and hemorrhage, leading to death. There is no commercially ready vaccine.
The information presented is for illustration only and is not intended to be relied upon by the reader for instruction as to the practice of medicine. Any health care practitioner reading this information is reminded that they must use their own learning, training and expertise in dealing with their individual patients. This material does not substitute for that duty and is not intended by Siemens Healthcare to be used for any purpose in that regard.
The drugs and doses mentioned herein are consistent with the approval labelling for uses and/or indications of the drug. The treating physician bears the sole responsibility for the diagnosis and treatment of patients, including drugs and doses prescribed in connection with such use. The Operating Instructions must always be strictly followed when operating the system. The source for the technical data is the corresponding data sheets. Results may vary.